Arylamine N-acetyltransferases: Structural and functional implications of polymorphisms

Abu-Zeid, 1991, An arylamine acetyltransferase (AT-I) from syrian golden hamster liver: cloning, complete nucleotide sequence, and expression in mammalian cells, Mol. Carcinog., 4, 81, 10.1002/mc.2940040112 Adam, 2003, Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro, Mol. Cancer Res., 1, 826 Ambrosone, 2008, Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: pooled analysis and meta-analysis, Cancer Epidemiol. Biomarkers Prev., 17, 15, 10.1158/1055-9965.EPI-07-0598 Anderton, 2006, Characterization of the putative operon containing arylamine N-acetyltransferase (nat) in Mycobacterium bovis BCG, Mol. Microbiol., 59, 181, 10.1111/j.1365-2958.2005.04945.x Andres, 1988, On the active site of liver acetyl-CoA, Arylamine N-acetyltransferase from rapid acetylator rabbits (III/J), J. Biol. Chem., 263, 7521, 10.1016/S0021-9258(18)68529-1 Badawi, 1995, Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder, Cancer Res., 55, 5230 Barker, 2006, Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1, Pharmacogenet. Genomics, 16, 515, 10.1097/01.fpc.0000215066.29342.26 Bhakta, 2004, Arylamine N-acetyltransferase is required for synthesis of mycolic acids and complex lipids in Mycobacterium bovis BCG and represents a novel drug target, J. Exp. Med., 199, 1191, 10.1084/jem.20031956 Blum, 1989, N-acetylation pharmacogenetics: a gene deletion causes absence of arylamine N-acetyltransferase in liver of slow acetylator rabbits, Proc. Natl. Acad. Sci. U.S.A., 86, 9554, 10.1073/pnas.86.23.9554 Blum, 1990, Human arylamine N-acetyltransferase genes: Isolation, chromosomal localization, and functional expression, DNA Cell Biol., 9, 193, 10.1089/dna.1990.9.193 Blum, 1991, Molecular mechanism of slow acetylation of drugs and carcinogens in humans, Proc. Natl. Acad. Sci. U.S.A., 88, 5237, 10.1073/pnas.88.12.5237 Boukouvala, 2002, Identification and functional characterization of novel polymorphisms associated with the genes for arylamine N-acetyltransferases in mice, Pharmacogenetics, 12, 385, 10.1097/00008571-200207000-00006 Boukouvala, 2003, Structure and transcriptional regulation of the Nat2 gene encoding for the drug-metabolizing enzyme arylamine N-acetyltransferase type 2 in mice, Biochem. J., 375, 593, 10.1042/bj20030812 Boukouvala, 2005, Arylamine N-acetyltransferases: what we learn from genes and genomes, Drug Metab. Rev., 37, 511, 10.1080/03602530500251204 Boukouvala, 2005, Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts, Basic Clin. Pharmacol. Toxicol., 96, 343, 10.1111/j.1742-7843.2005.pto_02.x Brooke, 2003, Synthesis and in vitro evaluation of novel small molecule inhibitors of bacterial arylamine N-acetyltransferases (NATS), Bioorg. Med. Chem. Lett., 13, 2527, 10.1016/S0960-894X(03)00484-0 Brooke, 2003, An approach to identifying novel substrates of bacterial arylamine N-acetyltransferases, Bioorg. Med. Chem., 11, 1227, 10.1016/S0968-0896(02)00642-9 Bruhn, 1999, Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1), Biochem. Pharmacol., 58, 1759, 10.1016/S0006-2952(99)00269-5 Butcher, 2003, Identification of a minimal promoter sequence for the human N-acetyltransferase type 1 gene that binds AP-1 (activator protein 1) and YY-1 (Yin and Yang 1), Biochem. J., 376, 441, 10.1042/bj20030650 Butcher, 2004, Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: A mechanism for the slow acetylator phenotype and substrate-dependent down-regulation, J. Biol. Chem., 279, 22131, 10.1074/jbc.M312858200 Cao, 2005, Only low levels of exogenous N-acetyltransferase can be achieved in transgenic mice, Pharmacogenomics J., 5, 255, 10.1038/sj.tpj.6500319 Cartwright, 1982, Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer, Lancet, 2, 842, 10.1016/S0140-6736(82)90810-8 Cornish, 2003, Generation and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 gene, Pharmacogenomics J., 3, 169, 10.1038/sj.tpj.6500170 Coroneos, 1993, Arylamine N-acetyltransferase activity in human cultured cell lines, Biochem. J., 294, 481, 10.1042/bj2940481 Dairou, 2006, Insight into the structure of Mesorhizobium loti arylamine N-acetyltransferase 2 (MLNAT2): a biochemical and computational study, FEBS Lett., 580, 1780, 10.1016/j.febslet.2006.02.033 Debiec-Rychter, 1996, Histological localization of messenger RNAs for rat acetyltransferases that acetylate serotonin and genotoxic arylamines, Cancer Res., 56, 1517 Deguchi, 1990, Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver, J. Biol. Chem., 265, 12757, 10.1016/S0021-9258(19)38219-5 Doll, 1995, Cloning, sequencing and expression of NAT1 and NAT2 encoding genes from rapid and slow acetylator inbred rats, Pharmacogenetics, 5, 247, 10.1097/00008571-199508000-00009 Doll, 2002, Rapid genotype method to distinguish frequent and/or functional polymorphisms in human N-acetyltransferase-1, Anal. Biochem., 301, 328, 10.1006/abio.2001.5520 Duke, 1999, Meningitis or madness: a delicate balance, J. Paediatr. Child Health, 35, 319, 10.1046/j.1440-1754.1999.00344.x Dupret, 1992, Site-directed mutagenesis of recombinant human arylamine N-acetyltransferase expressed in Escherichia coli. Evidence for direct involvement of Cys68 in the catalytic mechanism of polymorphic human NAT2, J. Biol. Chem., 267, 7381, 10.1016/S0021-9258(18)42528-8 Evans, 1964, Human acetylation polymorphism, J. Lab. Clin. Med., 63, 394 Fakis, 2000, Chromosome mapping of the genes for murine arylamine N-acetyltransferases (NATs), enzymes involved in the metabolism of carcinogens: identification of a novel upstream noncoding exon for murine Nat2, Cytogenet. Cell Genet., 90, 134, 10.1159/000015648 Flammang, 1987, The S-acetyl coenzyme A-dependent metabolic activation of the carcinogen N-hydroxy-2-aminofluorene by human liver cytosol and its relationship to the aromatic amine N-acetyltransferase phenotype, Carcinogenesis, 8, 1967, 10.1093/carcin/8.12.1967 Fretland, 1997, Cloning, sequencing, and recombinant expression of NAT1, NAT2, and NAT3 derived from the C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse: functional characterization of the activation and deactivation of aromatic amine carcinogens, Toxicol. Appl. Pharmacol., 142, 360, 10.1006/taap.1996.8036 Fullam, 2008, Divergence of cofactor recognition across evolution: coenzyme A binding in a prokaryotic arylamine N-acetyltransferase, J. Mol. Biol., 375, 178, 10.1016/j.jmb.2007.10.019 Goodfellow, 2000, Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2, Biochem. J., 348, 159, 10.1042/0264-6021:3480159 Grant, 1997, Human acetyltransferase polymorphisms, Mutat. Res., 376, 61, 10.1016/S0027-5107(97)00026-2 Hayes, 1993, N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers, Carcinogenesis, 14, 675, 10.1093/carcin/14.4.675 Hein, 2006, N-acetyltransferase 2 genetic polymorphism: Effects of carcinogen and haplotype on urinary bladder cancer risk, Oncogene, 25, 1649, 10.1038/sj.onc.1209374 Hein, 2008, Changes in consensus arylamine N-acetyltransferase gene nomenclature, Pharmacogenet. Genomics, 18, 367, 10.1097/FPC.0b013e3282f60db0 Hickman, 1991, N-Acetyltransferase polymorphism, Comparison of phenotype and genotype in humans, Biochem. Pharmacol., 42, 1007, 10.1016/0006-2952(91)90282-A Holton, 2005, Structure of Mesorhizobium loti arylamine N-acetyltransferase 1, Acta Crystallogr. F: Struct. Biol. Cryst. Commun., 61, 14, 10.1107/S1744309104030659 Hubbard, 1997, N-Acetyltransferase 2 genotype in colorectal cancer and selective gene retention in cancers with chromosome 8p deletions, Gut, 41, 229, 10.1136/gut.41.2.229 Husain, 2004, Identification of the major promoter and non-coding exons of the human arylamine N-acetyltransferase 1 gene (NAT1), Pharmacogenetics, 14, 397, 10.1097/01.fpc.0000114755.08559.6e Jenne, 1965, Partial purification and properties of the isoniazid transacetylase in human liver. Its relationship to the acetylation of p-aminosalicylic acid, J. Clin. Invest., 44, 1992, 10.1172/JCI105306 Jensen, 2006, Loss of function polymorphisms in NAT1 protect against spina bifida, Hum. Genet., 120, 52, 10.1007/s00439-006-0181-6 Johnson, N., 2001. The role of human arylamine N-acetyltransferase in development and disease. DPhil Thesis, The University of Oxford. Johnson, 2004, NAT gene polymorphisms and susceptibility to Alzheimer's disease: identification of a novel NAT1 allelic variant, BMC Med. Genet., 5, 6, 10.1186/1471-2350-5-6 Jones, 1996, Recombinant rat and hamster N-acetyltransferases-1 and -2: relative rates of N-acetylation of arylamines and N,O-acyltransfer with arylhydroxamic acids, Carcinogenesis, 17, 1729, 10.1093/carcin/17.8.1729 Josephy, 1998, Metabolic activation of aromatic amine mutagens by simultaneous expression of human cytochrome P450 1A2, NADPH-cytochrome P450 reductase, and N-acetyltransferase in Escherichia coli, Chem. Res. Toxicol., 11, 70, 10.1021/tx970171q Kawamura, A., 2005. Structural investigations of arylamine N-acetyltransferases from eukaryotes. DPhil Thesis, University of Oxford. Kawamura, 2005, Eukaryotic arylamine N-acetyltransferase. Investigation of substrate specificity by high-throughput screening, Biochem. Pharmacol., 69, 347, 10.1016/j.bcp.2004.09.014 Kawamura, 2008, Mouse N-acetyltransferase type 2, the homologue of human N-acetyltransferase type 1, Biochemical Pharmacology, 75, 1550, 10.1016/j.bcp.2007.12.012 Kelly, 1994, Arylamine N-acetyltransferase in Balb/c mice: Identification of a novel mouse isoenzyme by cloning and expression in vitro, Biochem. J., 302, 347, 10.1042/bj3020347 King, 1974, Mechanism of reaction, tissue distribution, and inhibition of arylhydroxamic acid acyltransferase, Cancer Res., 34, 1503 Klein, 2007, Arylalkylamine N-acetyltransferase: “the timezyme”, J. Biol. Chem., 282, 4233, 10.1074/jbc.R600036200 Lammer, 2004, Periconceptional multivitamin intake during early pregnancy, genetic variation of acetyl-N-transferase 1 (NAT1), and risk for orofacial clefts, Birth Defects Res. A: Clin. Mol. Teratol., 70, 846, 10.1002/bdra.20081 Land, 1994, Biochemical and genetic analysis of two acetyltransferases from hamster tissues that can metabolize aromatic amine derivatives, Carcinogenesis, 15, 1585, 10.1093/carcin/15.8.1585 Leff, 1999, Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse, J. Pharmacol. Exp. Ther., 290, 182 Liu, 2006, Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation, J. Mol. Biol., 361, 482, 10.1016/j.jmb.2006.06.029 Martell, 1991, Molecular genetic basis of rapid and slow acetylation in mice, Mol. Pharmacol., 40, 218 Martell, 1992, Cloned mouse N-acetyltransferases: enzymatic properties of expressed Nat-1 and Nat-2 gene products, Mol. Pharmacol., 42, 265 Matas, 1997, Mapping AAC1, AAC2 and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours, Cytogenet. Cell Genet., 77, 290, 10.1159/000134601 Minchin, 1995, Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells, Biochem. J., 307, 1, 10.1042/bj3070001 Minchin, 2007, Arylamine N-acetyltransferase 1, Int. J. Biochem. Cell Biol., 39, 1999, 10.1016/j.biocel.2006.12.006 Mitchell, 1999, Developmental expression of N-acetyltransferases in C57BI/6 mice, Drug Metab. Dispos., 27, 261 Mushtaq, 2002, The COOH terminus of arylamine N-acetyltransferase from Salmonella typhimurium controls enzymic activity, J. Biol. Chem., 277, 12175, 10.1074/jbc.M104365200 Nakura, 1995, Evidence for the lack of hepatic N-acetyltransferase in suncus (Suncus murinus), Biochem. Pharmacol., 50, 1165, 10.1016/0006-2952(95)00252-U Ohsako, 1988, Arylamine N-acetyltransferase from chicken liver. II. Cloning of cDNA and expression in Chinese hamster ovary cells., J. Biol. Chem., 263, 7534, 10.1016/S0021-9258(18)68531-X Ohsako, 1990, Cloning and expression of cdnas for polymorphic and monomorphic arylamine N-acetyltransferases from human liver, J. Biol. Chem., 265, 4630, 10.1016/S0021-9258(19)39609-7 Pacifici, 1986, Acetyltransferase in humans: development and tissue distribution, Pharmacology, 32, 283, 10.1159/000138181 Patin, 2006, Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes, Am. J. Hum. Genet., 78, 423, 10.1086/500614 Payton, 1999, Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: increased expression results in isoniazid resistance, J. Bacteriol., 181, 1343, 10.1128/JB.181.4.1343-1347.1999 Payton, 1999, A method for genotyping murine arylamine N-acetyltransferase type 2 (NAT2): a gene expressed in preimplantation embryonic stem cells encoding an enzyme acetylating the folate catabolite p-aminobenzoylglutamate, Biochem. Pharmacol., 58, 779, 10.1016/S0006-2952(99)00171-9 Payton, 2001, Evidence towards the role of arylamine N-acetyltransferase in Mycobacterium smegmatis and development of a specific antiserum against the homologous enzyme of Mycobacterium tuberculosis, Microbiology, 147, 3295, 10.1099/00221287-147-12-3295 Payton, 2001, Eubacterial arylamine N-acetyltransferases—identification and comparison of 18 members of the protein family with conserved active site cysteine, histidine and aspartate residues, Microbiology, 147, 1137, 10.1099/00221287-147-5-1137 Payton, 1998, Genotyping human arylamine N-acetyltransferase type 1 (NAT1): the identification of two novel allelic variants, Biochem. Pharmacol., 55, 361, 10.1016/S0006-2952(97)00478-4 Perry, 1973, Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis, Am. J. Med., 54, 58, 10.1016/0002-9343(73)90084-3 Pluvinage, 2007, Cloning and molecular characterization of three arylamine N-acetyltransferase genes from Bacillus anthracis: identification of unusual enzymatic properties and their contribution to sulfamethoxazole resistance, Biochemistry, 46, 7069, 10.1021/bi700351w Pluvinage, 2007, Crystallization and preliminary X-ray characterization of arylamine N-acetyltransferase C (BanatC) from Bacillus anthracis, Acta Crystallogr. F: Struct. Biol. Cryst. Commun., 63, 862, 10.1107/S1744309107041814 Pompeo, 2002, Expression and purification of the rifamycin amide synthase, RifF, an enzyme homologous to the prokaryotic arylamine N-acetyltransferases, Protein Exp. Purif., 24, 138, 10.1006/prep.2001.1550 Rengarajan, 2005, Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages, Proc. Natl. Acad. Sci. U.S.A., 102, 8327, 10.1073/pnas.0503272102 Rey, 1998, Isoniazid dose adjustment in a pediatric population, Ther. Drug Monit., 20, 50, 10.1097/00007691-199802000-00009 Riddle, 1971, Acetyl-coenzyme A: arylamine N-acetyltransferase. Role of the acetyl-enzyme intermediate and the effects of substituents on the rate, J. Biol. Chem., 246, 3250, 10.1016/S0021-9258(18)62221-5 Risch, 1995, Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer, Hum. Mol. Genet., 4, 231, 10.1093/hmg/4.2.231 Rodrigues-Lima, 2006, Cloning, functional expression and characterization of Mesorhizobium loti arylamine N-acetyltransferases: rhizobial symbiosis supplies leguminous plants with the xenobiotic N-acetylation pathway, Mol. Microbiol., 60, 505, 10.1111/j.1365-2958.2006.05114.x Rothman, 2007, Commentary: reflections on G. M. Lower and colleagues’ 1979 study associating slow acetylator phenotype with urinary bladder cancer: meta-analysis, historical refinements of the hypothesis, and lessons learned, Int. J. Epidemiol., 36, 23, 10.1093/ije/dym026 Sandy, 2002, The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis—an enzyme which inactivates the anti-tubercular drug, isoniazid, J. Mol. Biol., 318, 1071, 10.1016/S0022-2836(02)00141-9 Sandy, 2005, Binding of the anti-tubercular drug isoniazid to the arylamine N-acetyltransferase protein from Mycobacterium smegmatis, Protein Sci., 14, 775, 10.1110/ps.041163505 Sandy, 2005, Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines, Biochem. J., 390, 115, 10.1042/BJ20050277 Sasaki, 1991, Molecular and genetic analyses of arylamine N-acetyltransferase polymorphism of rabbit liver, J. Biol. Chem., 266, 13243, 10.1016/S0021-9258(18)98830-7 Sholto-Douglas-Vernon, 2005, Mutational and expression analysis of tbnat and its response to isoniazid, J. Med. Microbiol., 54, 1189, 10.1099/jmm.0.46153-0 Sikora, 2008, Kinetic mechanism and characterization of arylamine N-acetyltransferase from Mycobacterium tuberculosis Sim, 1984, Drugs that induce systemic lupus erythematosus inhibit complement component C4, Lancet, 2, 422, 10.1016/S0140-6736(84)92905-2 Sim, 1991, Polymorphism in human N-acetyltransferase—the case of the missing allele, Trends Pharmacol. Sci., 12, 211, 10.1016/0165-6147(91)90553-5 Sim, 2003, Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function, Biochem. Soc. Trans., 31, 615, 10.1042/bst0310615 Sim, 2007, Arylamine N-acetyltransferases, Expert Opin. Drug Metab. Toxicol., 3, 169, 10.1517/17425255.3.2.169 Sim, E., Fullam, E., Wakefield, L., in press-a. Arylamine N-acetyltransferases, in: Guengerich, F. (Ed.), Comprehensive Toxicology. Elsevier. Sim, 2008, Arylamine N-acetyltransferases: from structure to function, Drug Metabolism Reviews, 40, 479, 10.1080/03602530802186603 Sim, 2008, Arylamine N-acetyltransferases in mycobacteria, Current Drug Metabolism, 9, 510, 10.2174/138920008784892100 Sinclair, 1997, A fragment consisting of the first 204 amino-terminal amino acids of human arylamine N-acetyltransferase one (NAT1) and the first transacetylation step of catalysis, Biochem. Pharmacol., 53, 11, 10.1016/S0006-2952(96)00592-8 Sinclair, 2000, Structure of arylamine N-acetyltransferase reveals a catalytic triad, Nat. Struct. Biol., 7, 560, 10.1038/76783 Smelt, 1998, Placental expression of arylamine n-acetyltransferases: Evidence for linkage disequilibrium between NAT1*10 and NAT2*4 alleles of the two human arylamine N-acetyltransferase loci NAT1 and NAT2, Pharmacol. Toxicol., 83, 149, 10.1111/j.1600-0773.1998.tb01461.x Smelt, 2000, Expression of arylamine N-acetyltransferases in pre-term placentas and in human pre-implantation embryos, Hum. Mol. Genet., 9, 1101, 10.1093/hmg/9.7.1101 Stacey, 1999, Arylamine N-acetyltransferase type 2 (NAT2), chromosome 8 aneuploidy, and identification of a novel NAT1 cosmid clone: an investigation in bladder cancer by interphase fish, Genes Chromosomes Cancer, 25, 376, 10.1002/(SICI)1098-2264(199908)25:4<376::AID-GCC10>3.0.CO;2-H Stanley, 1998, Immunochemical detection of arylamine N-acetyltransferase during mouse embryonic development and in adult mouse brain, Teratology, 58, 174, 10.1002/(SICI)1096-9926(199811)58:5<174::AID-TERA3>3.0.CO;2-Q Sugamori, 2004, NAT3 knockout or overexpression in mice has no influence on N-acetylation activity, Drug Metab. Rev., 36, 164 Sugamori, 2003, Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice, Mol. Pharmacol., 64, 170, 10.1124/mol.64.1.170 Sugamori, 2006, In vivo and in vitro metabolism of arylamine procarcinogens in acetyltransferase-deficient mice, Drug Metab. Dispos., 34, 1697, 10.1124/dmd.106.010819 Suzuki, 2007, Arylamine N-acetyltransferase responsible for acetylation of 2-aminophenols in Streptomyces griseus, J. Bacteriol., 189, 2155, 10.1128/JB.01708-06 Swaim, 2006, Mycobacterium marinum infection of adult zebrafish causes caseating granulomatous tuberculosis and is moderated by adaptive immunity, Infect. Immun., 74, 6108, 10.1128/IAI.00887-06 Taioli, 1999, International collaborative study on genetic susceptibility to environmental carcinogens, Cancer Epidemiol. Biomarkers Prev., 8, 727 Thygesen, 1999, Genes for human arylamine N-acetyltransferases in relation to loss of the short arm of chromosome 8 in bladder cancer, Pharmacogenetics, 9, 1, 10.1097/00008571-199902000-00001 Trepanier, 1997, Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes, Biochem. Pharmacol., 54, 73, 10.1016/S0006-2952(97)00140-8 Trepanier, 1998, Deficiency of cytosolic arylamine N-acetylation in the domestic cat and wild felids caused by the presence of a single NAT1-like gene, Pharmacogenetics, 8, 169, 10.1097/00008571-199804000-00009 Trinidad, 1989, Kinetic characterization of acetylator genotype-dependent and -independent N-acetyltransferase isozymes in homozygous rapid and slow acetylator inbred hamster liver cytosol, Drug Metab. Dispos., 17, 238 Upton, 2001, Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism, Mol. Microbiol., 42, 309, 10.1046/j.1365-2958.2001.02648.x Vatsis, 1997, Acetyltransferases Wagner, 1996, Arylamine N-acetyltransferases: expression in Escherichia coli, purification, and substrate specificities of recombinant hamster monomorphic and polymorphic isozymes, Drug Metab. Dispos., 24, 245 Wakefield, 2005, Arylamine n-acetyltransferase 2 expression in the developing heart, J. Histochem. Cytochem., 53, 583, 10.1369/jhc.4A6496.2005 Wakefield, 2007, Deletion of a xenobiotic metabolizing gene in mice affects folate metabolism, Biochem. Biophys. Res. Commun., 364, 556, 10.1016/j.bbrc.2007.10.026 Wakefield, 2007, Ocular defects associated with a null mutation in the mouse arylamine N-acetyltransferase 2 gene, Mamm. Genome, 18, 270, 10.1007/s00335-007-9010-z Wakefield, 2008, Mouse arylamine N-acetyltransferase 2 (Nat2) expression during embryogenesis: a potential marker for the developing neuroendocrine system, Biomarkers, 13, 106, 10.1080/13547500701673529 Wakefield, 2008, Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors, Genes Chromosomes Cancer, 47, 118, 10.1002/gcc.20512 Walraven, 2007, Tissue expression and genomic sequences of rat N-acetyltransferases rNat1, rNat2, rNat3, and functional characterization of a novel rNat3*2 genetic variant, Toxicol. Sci., 99, 413, 10.1093/toxsci/kfm159 Walraven, 2007, Computational and experimental analyses of mammalian arylamine N-acetyltransferase structure and function, Drug Metab. Dispos., 35, 1001, 10.1124/dmd.107.015040 Walraven, 2006, Identification and characterization of functional rat arylamine N-acetyltransferase 3: comparisons with rat arylamine N-acetyltransferases 1 and 2, J. Pharmacol. Exp. Ther., 319, 369, 10.1124/jpet.106.108399 Walraven, 2008, Structure-function analyses of single nucleotide polymorphisms in human N-acetyltransferase 1, Drug Metab. Rev., 40, 169, 10.1080/03602530701852917 Wang, 2005, Catalytic mechanism of hamster arylamine N-acetyltransferase 2, Biochemistry, 44, 11295, 10.1021/bi047564q Wang, 2005, Irreversible inactivation of arylamine N-acetyltransferases in the presence of N-hydroxy-4-acetylaminobiphenyl: A comparison of human and hamster enzymes, Chem. Res. Toxicol., 18, 183, 10.1021/tx049801w Ward, 1995, Purification of recombinant human N-acetyltransferase type 1 (NAT1) expressed in E. coli and characterization of its potential role in folate metabolism, Biochem. Pharmacol., 49, 1759, 10.1016/0006-2952(95)00087-G Watanabe, 1992, J. Biol. Chem., 267, 8429, 10.1016/S0021-9258(18)42462-3 Weber, 1985, N-Acetylation pharmacogenetics, Pharmacol. Rev., 37, 25 Westwood, 2005, Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase, Biochem. J., 385, 605, 10.1042/BJ20041330 Westwood, 2006, Structure and mechanism of arylamine N-acetyltransferases, Curr. Top. Med. Chem., 6, 1641, 10.2174/156802606778108979 Westwood, 2007, Kinetic characterisation of arylamine N-acetyltransferase from Pseudomonas aeruginosa, BMC Biochem., 8, 3, 10.1186/1471-2091-8-3 Windmill, 2000, Localization of N-acetyltransferases NAT1 and NAT2 in human tissues, Toxicol. Sci., 54, 19, 10.1093/toxsci/54.1.19 Wu, 2007, Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases, J. Biol. Chem., 282, 30189, 10.1074/jbc.M704138200 Yamamoto, 1996, Demonstration of slow acetylator genotype of N-acetyltransferase in isoniazid neuropathy using an archival hematoxylin and eosin section of a sural nerve biopsy specimen, J. Neurol. Sci., 135, 51, 10.1016/0022-510X(95)00254-Y Yu, 1999, Direct evidence that the rifamycin polyketide synthase assembles polyketide chains processively, Proc. Natl. Acad. Sci. U.S.A., 96, 9051, 10.1073/pnas.96.16.9051 Zhang, 2006, NMR-based model reveals the structural determinants of mammalian arylamine N-acetyltransferase substrate specificity, J. Mol. Biol., 363, 188, 10.1016/j.jmb.2006.08.026 Zhu, 2006, Simultaneous determination of 7 N-acetyltransferase-2 single-nucleotide variations by allele-specific primer extension assay, Clin. Chem., 52, 1033, 10.1373/clinchem.2005.063198 Zhu, Y., Hein, D.W., 2007. Functional effects of single nucleotide polymorphisms in the coding region of human N-acetyltransferase 1. Pharmacogenomics J., Epub ahead of print.